

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**POLL RESULTS OF THE ANNUAL GENERAL MEETING
HELD ON FRIDAY, 26 JUNE 2026**

Reference is made to the circular (the “**Circular**”) of Everest Medicines Limited (the “**Company**”) incorporating, amongst others, the notice (the “**Notice**”) of the annual general meeting of the Company (the “**AGM**”) dated 3 June 2026. Unless the context requires otherwise, the capitalized terms used herein shall have the same meanings as those defined in the Circular.

On 26 June 2026, the AGM was held by way of virtual meeting via the Online Platform and all the proposed resolutions as set out in the Notice were duly passed by the Shareholders by way of poll. The poll results in respect of the resolutions proposed at the AGM are as follows:

Ordinary Resolutions		Number of Votes (%)	
		For	Against
1.	To receive and adopt the audited consolidated financial statements of the Company for the year ended 31 December 2025 and the reports of the directors of the Company (the “ Directors ”) and independent auditor of the Company (the “ Auditor ”) thereon.	122,433,310 (97.00%)	3,816,301 (3.00%)
2(a).	To re-elect Mr. Yifang Wu as an executive Director.	122,263,194 (97.14%)	3,595,406 (2.86%)
2(b).	To re-elect Mr. Wei Fu as a non-executive Director.	122,838,994 (97.73%)	2,851,056 (2.27%)
2(c).	To re-elect Mr. William Ki Chul Cho as a non-executive Director.	122,856,544 (97.75%)	2,825,056 (2.25%)

Ordinary Resolutions		Number of Votes (%)	
		For	Against
2(d).	To re-elect Mr. Xin Sun as a non-executive Director.	122,960,544 (97.88%)	2,663,056 (2.12%)
2(e).	To re-elect Ms. Hoi Yam Chui as an independent non-executive Director.	122,667,824 (97.70%)	2,881,776 (2.30%)
2(f).	To authorize the board of Directors (the “ Board ”) to fix the remuneration of the Directors.	123,029,142 (97.93%)	2,599,958 (2.07%)
3.	To re-appoint Ernst & Young as the Auditor to hold office until the conclusion of the next annual general meeting of the Company and to authorize the Board to fix their remuneration.	123,094,299 (97.90%)	2,642,301 (2.10%)
4.	To give a general mandate to the Directors to repurchase shares of the Company not exceeding 10% of the total number of issued shares of the Company (excluding any treasury shares) as at the date of passing of this resolution.	123,187,299 (98.04%)	2,458,301 (1.96%)
5.	To give a general mandate to the Directors to issue, allot and deal with additional shares of the Company (including any sale and transfer of treasury shares) not exceeding 20% of the total number of issued shares of the Company (excluding any treasury shares) as at the date of passing of this resolution.	110,325,728 (87.17%)	16,241,872 (12.83%)
6.	To extend the general mandate granted to the Directors to issue, allot and deal with additional shares in the capital of the Company (including any sale and transfer of treasury shares) by the aggregate number of the shares repurchased by the Company.	109,494,478 (87.22%)	16,037,622 (12.78%)

Notes:

- (a) As a majority of the votes were cast in favour of each of the resolutions numbered 1 to 6, such resolutions were duly passed as ordinary resolutions of the Company. The full text of the aforesaid resolutions is set out in the Circular.
- (b) As at the date of the AGM, (i) the total number of Shares in issue was 353,822,975 Shares; and (ii) there were no treasury Shares held by the Company (including any treasury Shares held or deposited with CCASS). Accordingly, the total number of Shares entitling the holders to attend and vote for or against the resolutions proposed at the AGM was 353,822,975 Shares.
- (c) The trustees holding unvested Shares awarded under the Company’s share schemes held 946,103 Shares as at the date of the AGM and were required under Rule 17.05A of the Listing Rules to abstain from voting on matters that require Shareholders’ approval under the Listing Rules.

- (d) Save as mentioned above, no shareholder of the Company was required under the Listing Rules to abstain from voting on the resolutions at the AGM and there were no Shares entitling the holder to attend and abstain from voting in favour as set out in Rule 13.40 of the Listing Rules.
- (e) None of the shareholders of the Company have stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions at the AGM.
- (f) The Company's Hong Kong share registrar, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote-taking at the AGM.
- (g) The AGM was chaired by Mr. Yifang Wu, and Mr. Wei Fu, Mr. Yongqing Luo, Mr. Ian Ying Woo, Mr. William Ki Chul Cho, Mr. Xin Sun, Ms. Hoi Yam Chui, Mr. Yifan Li and Mr. Shidong Jiang attended the AGM.

By order of the Board
Everest Medicines Limited
Yifang Wu
Chairman and Executive Director

Hong Kong, 26 June 2026

As at the date of this announcement, the Board comprises Mr. Yifang Wu as Chairman and Executive Director, Mr. Yongqing Luo and Mr. Ian Ying Woo as Executive Directors, Mr. Wei Fu, Mr. William Ki Chul Cho and Mr. Xin Sun as Non-executive Directors, and Ms. Hoi Yam Chui, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.